Capsulized Vs Fresh Fecal Microbiota Transplantation in Patients with Slow Transit Constipation: A Randomized Clinical Trial

Hongliang Tian,Jianfeng Gong,Ning Li

DOI: https://doi.org/10.14309/00000434-201610001-00542

2016-01-01

Abstract:Introduction: Fecal microbiota transplantation (FMT) has been shown to be effective in treating slow transit constipation, but practical barriers and safety concerns have prevented its widespread use. To determine the efficacy and safety whether capsulized FMT (C-FMT) is noninferior to fresh FMT (F-FMT) in terms of clinical efficacy among patients with slow transit constipation and to assess the safety of both types of FMT. Methods: We compared the outcomes of patients with constipation who had undergone fresh-FMT (n = 30) through nasoduodenal tube or oral capsulized feces (n = 30). Effectiveness and safety was defined as clinical symptoms improvement and adverse event reported. Results: A total of 60 patients (n = 30 in the C-FMT group and n = 30 in the F-FMT group) were included. There were no statistically significant differences in clinical improvement rate (50% vs. 54.5%, P = 0.292), clinical remission rate (32.1% vs. 38.5%, P = 0.432), No. bowel movement per weeks (P =0.231) and wexner constipation score (P =0.457) between two groups in the intention-to-treat (ITT) and per-protocol (PP) analysis. Compared with capsulized FMT group, fresh FMT group exhibited better results in stool consistency score (ITT: 5.0 vs. 4.1, P = 0.009; PP: 5.6 vs. 4.5, P = 0.002) and colonic transit time (CTT) (ITT: 67.5 vs. 59.3 h, P = 0.007; PP: 69.2 vs. 58.3 h, P = 0.006). 93.3% patients were more willing to choose capsulized FMT than the fresh FMT (60%).Fresh FMT group had more treatment related adverse events than capsulized FMT (90 vs. 27, P =0.007).Table 1: Patient demography and constipation history, all treated patientsTable 2: Treatment efficacy during a 12-week observation period: Capsulized vs. Fresh groups [intention-to-treat (ITT) and per-protocol (PP) analysis]Conclusion: Preparation of capsulized FMT simplifies the practical aspects of feces microbiota transplantation and less adverse events.However, long-term efficacy is less stable than the F-FMT group, which should be focused on in the future study.